Experiences of predictive genetic testing in inherited motor neuron disease: Findings from a qualitative interview study

Author:

Howard Jade1ORCID,Forrest Keenan Karen2,Mazanderani Fadhila3,Turner Martin R.4,Locock Louise5

Affiliation:

1. Sheffield Institute for Translational Neuroscience University of Sheffield Sheffield UK

2. Epidemiology Group University of Aberdeen Aberdeen UK

3. Science, Technology and Innovation Studies University of Edinburgh Edinburgh UK

4. Nuffield Department of Clinical Neurosciences University of Oxford Oxford UK

5. Health Services Research Unit University of Aberdeen Aberdeen UK

Abstract

AbstractPredictive genetic testing is increasingly available for individuals with a heightened risk of motor neuron disease (MND). However, little is known about how they decide whether or not to get tested, and how they experience this process. This paper reports findings from a constructivist grounded theory‐informed interview study with 24 family members of people with identified or suspected inherited MND (iMND). Fourteen did not know their genetic status, and nine had decided to have predictive testing, of whom six tested positive for the pathogenic gene variant identified in their family and three tested negative. One additional person was identified as negative through a parent's negative result. This paper explores the diverse ways people approached testing, and the many factors and motivations involved, based on personal attitudes and goals, experiences of living with genetic risk, and wider family considerations and circumstances. Results were met with a range of emotions; whatever the outcome, the news disrupted each person's view of the future, and they adapted in their own way and time. Support after results was variable and a perceived lack of support impacted coping and the ability to move forwards. This paper situates findings against literature on other genetic conditions, highlighting experiences as grounded in the unique characteristics of iMND. Thus, it emphasizes the need for disease‐specific guidelines and support structures around predictive genetic testing in this context. Understanding people's experiences and responding to these needs is particularly timely given the uptake of testing amongst this group is anticipated to rise with increasing access to genetic testing for people with MND, and gene‐specific clinical trials.

Funder

Motor Neurone Disease Association

University of Aberdeen

Publisher

Wiley

Reference53 articles.

1. Biogen. (2023).FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1‐ALS a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS.https://investors.biogen.com/news‐releases/news‐release‐details/fda‐grants‐accelerated‐approval‐qalsodytm‐tofersen‐sod1‐als

2. Amyotrophic Lateral Sclerosis

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3